Search

Displaying results 4161 - 4170 of 7059 in total
  1. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. … [A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889]

    Categories: Compounds used in a research, industrial, or household settingProducts: CARVEDILOL 1A PHARMA 25MG, CARVEDILOL 1A PHARMA 50MG
  2. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist. … [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]

  3. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH.

  4. Drug

    Avibactam

    go.drugbank.com/drugs/DB09060
    ApprovedInvestigational

    Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract

  5. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    Palopegteriparatide is a prodrug consisting of PTH(1-34) conjugated to a methoxy polyethylene glycol carrier (mPEG) via a proprietary TransCon Linker. … Palopegteriparatide is a parathyroid hormone (PTH) analog.

    Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34
  6. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … Clesrovimab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeted against the extracellular domain of the respiratory syncytial virus (RSV) fusion (F) protein.

  7. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome

    Products: Somatuline Autogel Prolonged Release Solution for Injection in a Pre-filled Syringe 120 mg, Somatuline Autogel Prolonged Release Solution for Injection in a Pre-filled Syringe 60 mg
  8. Drug

    Copper gluconate

    go.drugbank.com/drugs/DB11246
    ApprovedInvestigational

    Copper gluconate is a copper salt of D-gluconic acid that displays a light blue to bluish-green color. … According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005

    Mixtures: Vitamin A C E W.niacinam.beta Car.and Min.
  9. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer

  10. Drug

    Marstacimab

    go.drugbank.com/drugs/DB17725
    ApprovedInvestigational

    Marstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology. … [L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant.